New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb ...

A study on FUO in Guinea found diverse bacterial and viral infections, frequent misdiagnoses, and high antibiotic resistance, ...

New research led by scientists at La Jolla Institute for Immunology reveals the workings of a human antibody called mAb 3A6, ...

Cryo-EM structure of Sudan ebolavirus glycoprotein complexed with its human endosomal receptor NPC1 - (https://www.nature.com ...

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which ...

A new study finds that the Sudan virus, a deadly Ebola relative, binds to human NPC1 receptors with nine times greater affinity than Ebola. Using cryo-electron microscopy, researchers mapped its ...

A new retrospective, laboratory-based observational study provides detailed insights into the causes of fevers of unknown ...

Ebola is rare, deadly and has multiple variants. There is a vaccine for the Zaire type. Now, trials for another strain are underway.

There are no approved vaccines or treatments for Sudan virus disease, which has a 40–70% fatality rate. To curb the ongoing ...

Ebola virus disease (EVD ... One is Ebanga — an antibody-based drug that prevents the virus from entering cells, thus slowing its spread through the body. A second drug is Inmazeb ...

The Ebola virus (EBOV) is notorious for causing severe hemorrhagic fever in humans, and its matrix protein, VP40, plays a crucial role in the virus's ability to assemble and bud from host cells.